Enzalutamide Monotherapy Shows Higher Survival and Metastasis-Free Rates Versus Leuprolide in High-Risk Biochemical Recurrence
Enzalutamide shows better outcomes than leuprolide for high risk prostate cancer recurrence
This Phase 3 randomized controlled trial evaluated enzalutamide monotherapy versus leuprolide alone in patients with high-risk biochemical r…
Men with high-risk prostate cancer recurrence lived longer and spread less cancer when taking enzalutamide alone instead of leuprolide alone…
Talazoparib plus enzalutamide shows high probability of benefit in Japanese mCRPC subgroup
New Math Brings Hope to Japanese Men With Advanced Prostate Cancer
A Bayesian reanalysis of phase III trial data in 116 Japanese patients with metastatic castration-resistant prostate cancer found a 98% prob…
New math suggests a two-drug combo likely works for Japanese men with advanced prostate cancer, even when original trial numbers looked unce…
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression.
New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…